Ten eleven translocation (TET) enzymes catalyse the oxidative reactions of 5-methylcytosine (5mC) to promote the demethylation process. The reaction intermediate 5-hydroxymethylcytosine (5hmC) has been shown to be abundant in embryonic stem cells and tissues but strongly depleted in human cancers. Genetic mutations of TET2 gene were associated with leukaemia, whereas TET1 downregulation has been shown to promote malignancy in breast cancer. Here we report that TET1 is downregulated in colon tumours from the initial stage. TET1 silencing in primary epithelial colon cells increase their cellular proliferation while its re-expression in colon cancer cells inhibits their proliferation and the growth of tumour xenografts even at later stages. We found that TET1 binds to the promoter of the DKK gene inhibitors of the WNT signalling to maintain them hypomethylated. Downregulation of TET1 during colon cancer initiation leads to repression, by DNA methylation, the promoters of the inhibitors of the WNT pathway resulting in a constitutive activation of the WNT pathway. Thus the DNA hydroxymethylation mediated by TET1 controlling the WNT signalling is a key player of tumour growth. These results provide new insights for understanding how tumours escape cellular controls.
INTRODUCTION
DNA methylation has an essential role in the remodelling of the chromatin structure during development and tissue differentiation. [1] [2] [3] [4] [5] Deficient DNA methylation establishment, due to mutation in DNA methyltransferases Dnmt3a or Dnmt3b, can lead to genetic diseases, such ICF syndrome, and differentiationassociated methylation patterns are found altered in the majority of human cancers. [6] [7] [8] [9] [10] Irregular DNA methylation patterns are often associated with the tumour cells, where a general hypomethylation takes place together with hypermethylation of specific regions. 7, 9, [11] [12] [13] Colon cancer is one of the most susceptible disease to the deregulation of DNA methylation, and often the tumour initiation is due to genetic mutation accomplished by epigenetic inactivation of the WNT pathway inhibitors. 10, [14] [15] [16] 5-Hydroxymethylcytosine (5hmC) is a recently discovered epigenetic modification catalysed by the ten eleven translocation (TET) proteins that mediate the sequential oxidation of 5methylcytosine (5mC) to 5hmC, leading to eventual DNA demethylation. [17] [18] [19] [20] [21] 5hmC is lost in human cancers, but the functional significance of this event is not still understood. [22] [23] [24] [25] Several mechanisms can lead to loss of 5hmC in cancers, including mutations in IDH or TET2 genes. [26] [27] [28] [29] Reduced levels of 5hmC, associated with mutations or reduced expression of TET genes, have been implicated in myeloproliferative disorders. [22] [23] [24] [25] [29] [30] [31] [32] [33] [34] Downregulation of TET1 has been shown to promote cancer invasion and metastasis. 35, 36 Here we show that TET1 downregulation is not only linked to tumour progression and malignancy but is also necessary for tumour initiation and growth. We reveal the molecular function of TET1 protein in cancer development and clarify the mechanism by which the WNT pathway inhibitors are epigenetically switched off during cellular transformation. This mechanism provides the explanation for specific promoter hypermethylations in cancer, which are TET dependent, whereas a general hypomethylated state could be caused by deregulation of the DNA methyltransferase machinery.
RESULTS

TET1 downregulation is an early event in cell transformation
We analysed the level TET1 and hydroxymethylation in colon tumours. We found that TET1 and 5hmC are strongly reduced in primary colon cancers with respect to the surrounding healthy tissue (Figures 1a and b ). Interestingly, in our samples TET1 was downmodulated independently from the tumour stage and the histopathological grade (Supplementary Figure S1a) . To understand how TET1 is regulated in tumours with respect in tumour initiation and progression, we analysed a metadata set from stages I to IV of colon, breast, lung and rectum primary tumours. Analysis of the genes differentially expressed in this cohort of 887 adenocarcinomas revealed that TET1, but not TET2 or TET3, was strongly downregulated in tumours since stage I (Supplementary Figure S1b ). These data demonstrate that TET1 downregulation is an early event in tumourigenesis. Quantitative reverse transcriptase-PCR (RT-qPCR) analysis showed TET1 expression in human colon tissues and in normal epithelial colon cells (CCD), which were positive for the 5hmC modification, while TET1 and 5hmC modification were almost undetectable in all the analysed colon cancer cell lines (Figures 1c and d ). To understand TET1 functional role in colon cells, we silenced TET1 in the normal CCD cells using two different short hairpin RNAs (shRNAs) (Supplementary Figure  S2a ). TET1-knockdown CCD cells showed an increase in cell proliferation (Supplementary Figure S2b ), suggesting that TET1 has a role in the control of cell growth. To perform a rescue experiment, we silenced TET1 using the two shRNA together to increase the knockdown efficiency and re-expressed TET1 by using a cDNA missing its 3′ untranslated region. TET1 reexpression in TET-silenced cell induced a full recovery of the level of 5hmC as well as a reduction of the cell proliferation rate (Figures 1e-g).
TET1 blocks colon cancer cell growth in vitro and in vivo
The above results show that TET1 is downregulated in colon cancers and that its downregulation in normal cells promotes cell proliferation. Next, we analysed the effects of TET1 re-expression on the growth of colon cancer cells. To this end, we first generated Caco-2 and SW48 human colorectal carcinoma cell lines stably expressing TET1 under the control of a doxycycline (Dox)-inducible promoter (Figure 2a ). TET1 expression did not alter TET2 or TET3 expression ( Supplementary Figures S3a and b ). Upon cell treatment with Dox, TET1 induced an increased level of 5hmC and strongly reduced the growth rate of both cell lines (Figures 2b and c). These effects were due to the enzymatic activity of TET1, which lengthens the G0/G1 phase of the cell cycle, whereas the hydroxylase-deficient mutant TET1-H1672Y/D1674A (TET1-mut) was not able to interfere with cell growth in vitro ( Supplementary Figures S3c-f ). As both Caco-2 and SW48 form spheres under serum-free conditions ( Supplementary Figures S4a  and b ), we also tested the effect of TET1-dependent hydroxymethylation on tumour-initiating cells. TET1 induction caused a significant reduction of sphere formation (Figure 2d ). We analysed the surface markers CD166, CD44 and EpCAM that increase during sphere growth, 37 but we did not observe any changes of these markers in Caco-2 or SW48 cells after TET1 re-expression, suggesting that TET1 decreases cell proliferation independently Figure S4c ). To evaluate whether TET1 has a role in tumour growth in vivo, we injected the Caco-2 and SW48 cell lines in nude mice. A group of animals were then treated with Dox to induce the expression of TET1 ( Figure 3a ). The size and weight of xenografts expressing TET1 were dramatically smaller than the control group in which TET1 was not induced (Figures 3b-d, and Supplementary Figure S5a ). TET1 expression blocked the growth of the tumours derived from both cell lines from the beginning ( Figure 3b ). Remarkably, growth arrest was obtained not only when TET1 was induced early after tumour cells' inoculation but also when TET1 was induced when the tumours were already established several days later (Figure 3e and Supplementary Figure S5b ). These results are consistent with the strong inhibition of cell growth observed in vitro.
TET1 inhibits WNT signalling pathway
To understand the molecular function of TET1 expression on colon cancer, we performed a genome-wide RNA-Seq analysis of the mRNA of Caco-2 cells treated for 96 h with Dox. This analysis revealed that TET1 alters the expression of about 300 genes of which 460% were upregulated ( Figure 4a ). Interestingly, analysis of the genome-wide methylation pattern of wild-type Caco-2 cells 38 showed that the genes upregulated by TET1 were those that exhibited a significant higher methylation level on their promoters ( Figure 4b ). Gene ontology analysis showed a significant enrichment in the WNT/β-catenin signalling pathway (P-value o0.001) of the TET1-deregulated genes, and many of them are involved directly or indirectly to the canonical WNT pathway (Figures 4c and d) . We measured the level of nuclear β-catenin (CTNNB1), and we observed its reduced nuclear localization after TET1 re-expression in both the cancer cell lines (Figures 4e and f). We then analysed the effect of TET1 expression on the WNT/β-catenin signalling pathway by using the TCF/LEFdependent luciferase reporter assay as these cancer cells show high activity of this pathway (Supplementary Figure S6a ). TET1 induced a downregulation of WNT/β-catenin signalling in both cell lines ( Figure 4g ). Also in this case, the enzymatic activity of TET1 was required to downmodulate the WNT pathway activity (Supplementary Figure S6b ). To demonstrate that the decreased proliferation rate was due to the TET1-dependent inactivation of the WNT pathway, we expressed a stable nuclear β-catenin in the Caco-2 and SW48 lines treated with Dox ( Figure 4h ). The expression of β-catenin in these cells rescued the luciferase activity and cell growth (Figure 4i and Supplementary Figure S6c ), demonstrating that the TET1-induced block of cell proliferation acts via WNT pathway inhibition. Interestingly, immunofluorescence analysis and western blotting of nuclear extracts of 24-dayold xenografts showed sustained β-catenin nuclear localization in untreated but not in Dox-treated mice (Supplementary Figures  S6d and e ), indicating that also in in vivo occurs a reduced WNT pathway activity in TET1-expressing tumours.
TET1-dependent demethylation promotes transcriptional activation of the WNT pathway inhibitors RNA-Seq analysis showed proliferation-associated genes downregulated in TET1-expressing Caco-2 cells, such as MYC and Cyclin D2 (CCND2) that are downstream targets of the WNT pathway. Importantly, DKK and SFRP genes, that are upstream inhibitors of TET1 in colon cancer the WNT pathway, were found upregulated in TET1-expressing cells (Figure 5a ). RT-qPCR analysis at 96 h after Dox treatment showed the upregulation of DKK3 and DKK4 and the downregulation of MYC and Cyclin D2 in both the cell lines ( Figure 5b ). Chromatin immunoprecipitation (ChIP) analysis showed the binding of TET1 on the promoters of DKK genes (Figure 5c ). Analysis of the level of 5hmC and 5mC revealed a significant increase of 5hmC on the DKK3 and DKK4 genes associated with a reduction of 5mC signal (Figures 5d and e ). Interestingly, DKK1 and DKK2 expression was not affected by TET1 (Figure 5b ). DKK1 was not methylated, suggesting that on this gene the transcriptional repression is not mediated by DNA methylation. DKK2 showed an elevated level of DNA methylation, which was not significantly reduced by TET1 expression at 96 h after Dox treatment (Figure 5e ). To demonstrate that TET1 functions via repressing of the WNT inhibitors, we performed a rescue experiment in which we silenced the DKK3 and DKK4 genes and re-expressed TET1 in Caco-2 and SW48 cells ( Figure 5f ). We used two different shRNAs to perform the knockdown of each DKK gene. The knockdown of both DKK3 and DKK4 restored the cell growth inhibition by TET1 expression (Figure 5g ). Interestingly, RT-qPCR analysis of Caco-2 and SW48 tumour xenografts at later time points showed DKK3 and DKK4 upregulation as well as MYC and Cyclin D2 downregulation (Supplementary Figure S7 ). It is worth noting that the tumours also expressed DKK2 (Supplementary Figure S7) , which was not upregulated within 96 h of TET1 expression (Figure 5b ), suggesting a cumulative TET1-dependent demethylation on the DKK2 promoter in xenografts.
Taken together, the above data demonstrate that TET1 inhibits cancer cells' growth by repressing the WNT pathway, via demethylation of the promoters of the WNT inhibitors DKK3 and DKK4. 
DISCUSSION
We here demonstrate that TET1 loss in colon cancer is an early event that favours cell proliferation. We propose a model by which TET1 downmodulation contributes to tumour initiation. Indeed, our data show that TET1 silencing in normal epithelial colon cells facilitates cell cycle progression and that its re-expression in transformed colon cells blocks cell growth. Accordingly, metaanalysis on a cohort of 887 adenocarcinomas showed that TET1 mRNA is downregulated from the first stage of tumours, especially in colon-rectal cancers. Thus the downmodulation of TET1 takes TET1 in colon cancer place already at their initial stage, suggesting that, in order to grow, cancer cells must downregulate TET1 expression. Our work demonstrated that TET1 downmodulation is required for cancer cell growth as its re-expression in cancer cells inhibits their growth both in vitro and in vivo. We found that TET1's oncosuppressor function is mediated by its enzymatic activity, as the catalytically dead mutant was unable to block cancer cell growth. DKK4  DKK3  SFRP5  SFRP4  SOX2  TCF1  AXIN1  AXIN2  ID3  WNT8B  MET  PPARA  MYC  PPARG  CCND2  DOX: -+ most affected genes WNT pathway The significant increase of 5hmC in TET1-expressing cells suggests that this modification could have gene regulatory functions in addition to being an intermediate for Cdemethylation. 39, 40 It has been previously shown in breast tissue that TET1 is required to maintain the expression of the antimetastatic miR200 and TIMP (tissue inhibitors of metalloproteinase) genes by inhibiting the methylation on their promoters, and its downregulation in breast cancer results in the lower expression of these genes. 35, 36 In contrast, in colon cancers, we could not find the expression of miR200 or the downregulation of TIMP genes (data not shown). Instead, we found that TET1 targeting the DKK and SFRP genes induced a reduction of the 5mC and an increase of the 5hmC marks on their promoter regions leading to the expression of these genes.
Thus, in colon tumours the downregulation of the inhibitors of the WNT pathway, DKKs and SFRPs, due to TET1 downmodulation, results in the increase of tumour growth. This implies that in different tissues, due to the cell-specific epigenetic landscape, cells respond with different phenotypic outputs to TET1 downmodulation.
WNT pathway inhibitors DKKs and SFRPs are epigenetically inactivated by DNA methylation in colorectal cancer cells, and this event is able to sustain tumour development. 14, 15, 41 Repression of these inhibitor genes allows a constitutive WNT signalling that sustains the proliferation of cancer cells. Our data demonstrate that the gain of DNA methylation on these promoters is due to the reduced TET1-dependent demethylation activity.
In colon cancer cells, the loss of TET1 promotes DNA methylation of these promoters leading to a full repression of the genes, which is revertible by TET1 re-expression.
In summary, our data show that TET1 acts as an oncosuppressor, because it has a central role in the epigenetic control of colon cancer growth. TET1 reactivation, although challenging, can represent a novel therapeutic approach in cancer.
MATERIALS AND METHODS
Cell culture, transfection and transduction
Caco-2 and SW48 cells were cultured in RPMI medium with 10% fetal calf serum. For Dox-inducible stable clone generation, Caco-2 and SW48 cells were transduced with 10 μl of concentrated virus of pLVX-Tight-Puro-TET1 and pLVX-Tet-On-Advanced Vectors and selected for 7 days in Puromycin 1 μg/ml and Hygromycin B 100 μg/ml. For induction of TET1, Dox was used at 1 μg/ml. Transfections were performed using the Lipofectamine 2000 Transfection Reagent (Invitrogen, San Diego, CA, USA) according to the manufacturer's protocol. CCD normal colon epithelial cells were acquired from ATCC (www.atcc.org) (CCD 841 CoN (ATCC CRL-1790) and cultured as described by ATCC. For shRNA transduction, 10 μl of concentrated virus of PLKO vectors were incubated with cells for 16 h. Animals C57BL/6 mice (8-10-weeks old) were obtained from our mouse facility. BALB/c-nude (6-weeks old) were obtained from Janvier-Labs (Le Genest-Saint-Islet, France). Housing and all experimental animal procedures were approved by the Institutional Animal Care and Research Advisory Committee of the University of Turin, Turin, Italy.
Constructs pAAV-EF1a-HA-hTet1CD-WPRE-PolyA and pAAV-EF1a-HA-hTet1CDmu-WPRE-PolyA were purchased from Addgene (Cambridge, MA, USA) (plasmid 39454 and 39455). pLVX-Tight-Puro Vector and pLVX-Tet-On-Advanced Vector were purchased from Clontech (Mountain View, CA, USA) (plasmid S4934 and S4932). Catalytic domain of TET1 was sub-cloned into pLVX-Tight-Puro-Vector. TET1, DKK3 and DKK4 shRNAs were constructed using the TRC hairpin design tool (http://www.broadinstitute.org/rnai/ public/seq/search) choosing the following hairpin sequences:
5′-ACACAACTTGCTTCGATAATT-3′ (TET1, shRNA1), 5′-TTGTGCCTCTGGAGGTTATAA-3′ (TET1, shRNA2); 5′-GACACGAAGGTTGGAAATAAT-3′ (DKK3, shRNA1), 5′-GGCATGCACATCTGGAATTAA-3′ (DKK3, shRNA2); 5′-TCGGCAGCATGCTCGATTAAG-3′ (DKK4, shRNA1), 5′-GGAAGCCAAGTATTAAGAAAT-3′ (DKK4, shRNA2). Annealed oligonucleotides were cloned into pLKO.1 vector (Addgene: 10878), and each construct was verified by sequencing. Super8X-TOPFlash, negative control Super8X-FOPFlash and pCS2-CTNNB1-S33A-myc-tag were kindly provided by Professor Valeria Poli.
Antibodies
The antibodies were purchased from Millipore (Temecula, CA, USA) (anti-TET1), Abcam (Cambridge, MA, USA) (anti-ssDNA), Cell Signalling (Danvers, MA, USA) (anti-CD44-8E2, anti-EpCAM), Sigma-Aldrich (Saint-Quentin Fallavier, France) (anti-β-actin), Epitomics (Cambridge, MA, USA) (anti-CD166), BD Transduction Laboratory (Franklin Lakes, NJ, USA) (anti-CTNNB1), Santa Cruz (Santa Cruz, CA, USA) (anti-LaminA-sc20680) and Active Motif (Vineland, ON, Canada) (anti-5mC, anti-5hmC).
DNA extraction and dot-blot analysis
Genomic DNA was extracted from cells using the DNeasy Blood and Tissue kit (Qiagen, Gmbh, Hilden, Germany). For dot-blot analysis, extracted genomic DNA was sonicated for 15 cycles to obtain 300-bp fragments, denatured with 0.4 M NaOH and incubated for 10 min at 95°C prior to being spotted onto HybondTM-N+ (GE Healthcare, Little Chalfont, UK). Membrane were saturated with milk 5% and incubated 16 h with the specific antibodies.
RNA extraction and RT-PCR analysis
RNA extraction and RT-PCR were performed as in Incarnato et al. 42 Briefly, total RNA was extracted using the TRIzol reagent (Invitrogen). Real-time PCR was performed using the SuperScript III Platinum One-Step Quantitative RT-PCR System (Invitrogen, cat.11732-020) following the manufacturer's instructions. Primers sequences are provided in Supplementary Table S1 .
RNA sequencing
For mRNA-Seq, libraries were generated from total RNA using TruSeq RNA Sample Preparation v2 according to the manufacturer's protocol. Samples were sequenced on Illumina HiScanSQ platform (Illumina, San Diego, CA, USA). Reads were mapped on hg19 using TopHat v2.0.6 (Johns-Hopkins University, Baltimore, MD, USA), 43 and mRNA quantification was performed using Cuffdiff v2.0.2 (University of Maryland, College Park, MD, USA). 44 Upregulated and downregulated genes are provided in Supplementary  Table S3 . Raw data are deposited under the GEO accession GSE53172.
ChIP and hMeDIP
ChIP were performed as in Evellin et al. 45 For MeDIP and hMeDIP, 2 μg of sonicated DNA was denatured at 95°C for 10 min, immediately cooled on ice for 10 min and diluted in 400 μl of IP buffer (10 mM Na-Phosphate pH 7.0 140 mM NaCl 0.05% Triton X-100) with 10 μl of anti-5mC or anti-5hmC. After incubation of 2 h with at 4°C with overhead shaking, 30 μl of saturated Dynabeads anti-mouse IgG were added and incubated for another 2 h. After five washes with IP buffer, DNA was eluted with Proteinase K for 2 h and purified using the QIAQuick PCR Purification Kit (Qiagen) according to the manufacturer's instructions. DNA was analysed by quantitative real-time PCR by using a SYBR GreenER kit (Invitrogen). Primers sequences are provided in Supplementary Table S2 .
Protein extraction and western blotting
Extracts were performed as previously described. 46 Briefly, cells were resuspended in F-buffer (10 mM TRIS-HCl pH 7.0, 50 mM NaCl, 30 mM Napyrophosphate, 50 mM NaF, anti-proteases) and sonicated for three pulses to obtain total cell extracts. Nuclear protein extraction was performed as in Neri et al., 3 and extracts were quantified using the bicinchoninic acid (BCA) assay (BCA protein assay kit; catalog no. 23225; Pierce, Thermo Scientific, Rockford, IL, USA) and were run in sodium dodecyl sulphatepolyacrylamide gels at different percentages, transferred to nitrocellulose membranes and incubated 16 h with specific primary antibodies.
TET1 in colon cancer
Luciferase assay
Cells were transfected with the indicated Firefly luciferase reporter constructs with 1/10 of Renilla Luciferase reporter construct. After 24 h, cells were analysed for luciferase and Renilla activity using a Dual-Glo luciferase assay (Promega, Madison, WI, USA). Promoter activity values were normalized using Renilla activity.
Immunofluorescence
For immunostaining, tumours were dissected and fixed in 2% PFA overnight at 4°C, dehydrated and embedded in paraffin. Thick sections (5-μm thickness) were then incubated with anti-CTNNB1 antibody.
Cell growth and cell cycle analysis
For cell growth assay, 5 × 10 4 cells were plated in 35-mm wells and counted at the indicated time points using the Scepter Automated Cell Counter (Millipore). For the FACS (fluorescence-activated cell sorting) cell cycle analysis, the cells were stained with propidium iodide solution (0.1% Triton, 200 mg/ml RNase, 20 mg/ml propidium iodide in phosphatebuffered saline) for 30 min at room temperature. Acquisition was performed using Becton Dickinson FACS Canto (San Jose, CA, USA), and analysis was done with the FACS FlowJo Software (Ashland, OR, USA).
FACS analysis
FACS analysis was performed as previously described. 47 Briefly, cells were first incubated with the primary antibodies for 30 min in phosphatebuffered saline -1% bovine serum albumin and, after three washes, were stained with conjugated secondary antibodies.
Colonsphere assay
Colonsphere assay was performed as in Kanwar et al. 37 with the following modifications: cells were plated as single cell in 96-well round bottom in Dulbecco's modified Eagle's medium/F12 medium supplemented with bovine serum albumin 0.4%, Heparin 4 μg/ml, Insulin 20 μg/ml, B27, N2, basic fibroblast growth factor 10 ng/ml, epidermal growth factor 20 ng/ml and cultured for 10 days before analysis.
Mouse and tumour injections
Caco-2 and SW48 human colon tumour cell lines were harvested, and single-cell suspensions of 1 × 10 6 in 100 ul of phosphate-buffered saline were injected subcutaneously into the right flank of mice. Tumour volumes were measured every 2 days with a calliper using the formula: V = π × (d 2 × D)/6, where d is the minor tumour axis and D is the major tumour axis. The mice were killed at defined time intervals after cell inoculation or when tumours reached a maximum size of 2 cm 3 .
Bioinformatics analysis
Gene expression analysis of TET1, TET2 and TET3 was performed using The Cancer Genome Atlas TCGA database (http://cancergenome.nih.gov/) subdividing the cancers for their reported tumour stage where it was available, otherwise the data were not used. Gene ontology was performed using the DAVID Software (Frederick National Laboratory, Rockville, MD, USA). 48, 49 
